中文摘要：

目的：研究长期口服普萘洛尔对血管瘤患儿体格发育的影响。方法：收集2010年1月-2014年8月就诊于山东大学齐鲁医院的血管瘤患儿资料，手术切除者为手术组．口服普萘洛尔治疗者为普萘洛尔组。于2014年12月通过电话、信件等方式收集患儿体格发育指标，以2组患儿体重、身高、坐高、头围、胸围、上臂围、体质指数、体重／身高、胸围／身高、坐高／身高等10项指标作为评价儿童体格发育标准．将获得的不同年龄和性别的2组指标数据分别与《中国七岁以下儿童生长参照标准》和WHO儿童正常生长指标进行比较，并以年龄、性别和居住地作为协变量，采用SPSS18．0软件包对2组患儿各项生长指标作协方差分析。结果：118例患儿（普萘洛尔组92例，手术组26例）纳入研究，经统计学分析，10项指标中仅身高和胸围有统计学差异（P=0．038〈0．05，P=0．041〈0．05），普萘洛尔组患儿身高、胸围均值分别较手术组低11．11cm和3．25cm。结论：长期口服普萘洛尔可能延缓血管瘤患儿的身高和胸围发育。

英文摘要：

PURPOSE： To investigate the effect of oral propranolol on growth and development of children with infantile hemangioma （IH）. METHODS： Children with IHs during Jan. 2010 and Aug. 2014 treated with surgery or oral propranolol in Qilu Hospital were recruited. The children were divided into surgery group and propranolol group. Phone calls and letters were used for investigation in December 2014. Ten indicators including weight, height （length）, sitting height, head circumstance, chest circumstance, upper limber circumstance, body weight index （BMI）, weight/height （length）, chest/height and sitting height/height were selected to evaluate their growth and development levels. The data were analyzed based on Chinese Growth Reference Standards under 7 and WHO Child Growth Standards, and tested by age, sex and place of residence as eovariates, covariance analysis. RESULTS： One hundred and eighteen cases （92 for propranolol and 26 for surgery） were included. Covariance analysis indicated significant differences of height and chest circumstance among 10 indicators between surgery and propranolol groups （P=0.038〈0.05, P=0.041 〈0.05）, and the height and chest of the propranolol were lower than those of surgery （11.11 cm and 3.25 cm） the average differences were 11.11 cm and 3.25 cm. CONCLUSIONS： Long-term oral propranolol may lead to hypoevolutism of height and chest circumference in children with IH.